Henoch-Schönlein Purpura Associated with Solid-Organ Malignancies: Three Case Reports and a Literature Review

Total Page:16

File Type:pdf, Size:1020Kb

Henoch-Schönlein Purpura Associated with Solid-Organ Malignancies: Three Case Reports and a Literature Review Included in the theme issue: INFLAMMATORY SKIN DISEASES Acta Derm Venereol 2012; 92: 388–392 Acta Derm Venereol 2012; 92: 339–409 CLINICAL REPORT Henoch-Schönlein Purpura Associated With Solid-organ Malignancies: Three Case Reports and a Literature Review Joshua O. PODJASEK, David A. WETTER, Mark R. PITTELKOW and David A. WADA Department of Dermatology, Mayo Clinic, Rochester, MN, USA Adult Henoch-Schönlein purpura (HSP) is rarely asso- Table I. Summary of characteristics of 47 previously reported ciated with solid-organ malignancies. We describe here patients with Henoch-Schönlein purpura associated with solid- a three adult patients with HSP diagnosed within 3 months organ malignancy of the diagnosis of associated solid-organ malignancies, Characteristic Value including pulmonary, prostate, and renal carcinomas. Age, years, mean 62b Two patients had complete remission with a combina- Men, n (%) 33 (70) c tion of immunosuppressive therapies and treatment of Type of solid-organ malignancy (n = 53) , n (%) Lung 14 (26) the associated malignancy. The third patient had partial Prostate 6 (11) remission with immunosuppressive therapies, but never Kidney 5 (9) received treatment for the associated malignancy and Gastric 4 (8) did not achieve complete remission before his death 10 Breast 3 (6) Thyroid 3 (6) months after diagnosis of HSP. These cases suggest that Carcinoid 2 (4) HSP associated with solid-organ malignancies may be Maxillary 2 (4) resistant to immunosuppressive therapies without treat- Cervical 2 (4) ment of the associated malignancy. Therefore, evaluation Colon 2 (4) Epiglottic, Hypopharyngeal 2 (4) for solid-organ malignancies should be considered in Esophageal 1 (2) adult patients without an identifiable cause of HSP, espe- Anal, Rectal 2 (4) cially if the disease is not self-limited or does not respond Ovarian, Endometrial 2 (4) appropriately to treatment. Key words: coagulation; cu- Hepatocellular, Cholangiocarcinoma 2 (4) Schwannoma 1 (2) taneous disease; immunopathology; immunofluorescence; Onset of cutaneous vasculitis in relation to microvascular occlusion syndrome; purpura; vasculitis. malignancy (n = 53)c, n (%) Before 14 (26) (Accepted October 3, 2011.) Synchronousd 19 (36) After 20 (38) Acta Derm Venereol 2012; 92: 388–392. Response of cutaneous vasculitis to treatment, n (%) Remission with immunosuppressive agents 3 (6) Remission with treatment of cancer 9 (19) David A. Wetter, Department of Dermatology, Mayo Remission with combined treatment 4 (9) Clinic, 200 First St SW, Rochester, MN 55905, USA. No remission 0 E-mail: [email protected] Unknown 31 (66) Outcome, n (%) Alive 8 (17) Deceased 14 (30) We recently described 17 cases of cutaneous small vessel Unknown 25 (53) vasculitis (CSVV) associated with solid-organ malignan- aThree cases described by Fain et al. (25) were not included because indivi- cies (1). In that study, CSVV was equivalent to leukocy- dual patient information was not available. toclastic vasculitis or hypersensitivity vasculitis (1), per bTwo cases had no record of patient age or sex. the inclusion criteria of Fiorentino (2). Similar to CSVV, cSix patients (cases 14, 18, 27, 33, 34, and 47 in Table SI) had 2 separate malignancies associated with HSP. Henoch-Schönlein purpura (HSP) has also previously d been associated with malignancy. However, in contrast to Occurred within 1 month of each other. CSVV, HSP has been reported to occur more commonly with solid-organ malignancies than with hematological HSP associated with solid-organ malignancies seen at malignancies (3, 4). In particular, pulmonary, prostatic, Mayo Clinic over the previous 13 years. and renal carcinomas have been most commonly as- sociated with the development of HSP (4). In total, 47 CASE REPORTS cases of HSP related to solid-organ malignancy have been This study was approved by the Mayo Clinic Institutional reported previously (Table I and Table SI; available from: Review Board. http://www.medicaljournals.se/acta/content/?doi=10.234 Case 1. A 47-year-old man presented with palpable purpura of 0/00015555-1288). We report here 3 additional cases of one week’s duration involving his lower extremities (Fig. 1A, Acta Derm Venereol 92 © 2012 The Authors. doi: 10.2340/00015555-1288 Journal Compilation © 2012 Acta Dermato-Venereologica. ISSN 0001-5555 lower lower extremity lesion indicated leukocytoclastic vasculitis, and hematuria and proteinuria on urinalysis. Skin biopsy of a ≤ (normal mm/h 56 of rate sedimentation erythrocyte an included purpura the of evaluation during values laboratory positive Pertinent metastases. nodal for cisplatin and etoposide with chemotherapy and radiotherapy subsequent and tumor the carcinoma had included bronchoscopy with laser ablation of the of Treatment T4N2M0). IIIb, (stage lung the of carcinoma she had received a diagnosis of months squamous earlier, cell purpura on her bilateral lower extremities (Table II). Three Case 2. has shownnosignsofrecurrenceafter28monthsfollow-up. HSP the and later, months 2 tapered was dapsone oral The loped. deve lesions new No improve. to continued symptoms systemic nephropathy. and C3,consistentwithIgA analysis of the glomeruli showed mesangial staining for IgA the initial diagnosis of Immunofluorescent HSP. histological after weeks 5 approximately nephrectomy partial underwent He revealed clear cell renal cell carcinoma (stage I, T1aNXM0). evaluation Further identified. was mass renal enhancing solid, domen to evaluate his abdominal pain and diarrhea. A 2-cm, continued toimprovethroughouta4-weekprednisonetaper. symptoms and lesions skin The prednisone. oral starting of days 2 within swelling uvular and arthritis, pain, abdominal rash, his in improvement significant had he initiated; was daily orally mg probably associated Treatment with with prednisone HSP. 60 evaluation determined that he had Otolaryngological uvular oropharynx. his swelling in fullness that of sensation was a and irritation experienced he addition, In diarrhea. and nausea, pain, abdominal with along hands, and ankles, knees, his in developed pain arthritic Concomitantly, 1B). (Fig. extremities lower distal number of large, crusted, necrotic increasing An lesions extremities. developed upper bilateral on and trunk the his involve fluocinonide 0.05%creamandtacrolimus0.1%ointment. topical as well as daily, twice orally mg 25 dapsone with begun was treatment and made, was HSP probable of diagnosis A turia. microhema revealed Urinalysis vessels. blood dermal superficial on samples of lesional skin revealed deposition of IgA within cytoclastic vasculitis. Direct immunofluorescence performed leuko demonstrated lesions representative of Biopsies II). Table plaques withsurroundingviolaceouserythemaalongtheanteriortibia. necrotic coalescent, occasionally Clustered, B. extremities. lower bilateral the 1. Fig. After the partial nephrectomy, the patient’s skin lesions and The patient underwent computed tomography of the ab Throughout the next several weeks, the lesions spread to A. Palpable purpura and several larger, necrotic, purpuric plaques on plaques purpuric necrotic, larger, several and purpura Palpable A. A 71-year-old woman was evaluated for palpable 22 mm/h) mm/h) 22 - - - - Table II. Characteristics of patients with Henoch-Schönlein purpura (HSP) associated with solid-organ malignancy Type of Age, Presenting features Onset of vasculitis in solid-organ Abnormal laboratory Treatment of solid- Response to Outcome, Case years/sex of HSP relation to malignancy malignancy valuesa Treatment of vasculitis organ malignancy treatment follow-upb Comment 1c 47/M Purpura, arthritis, Synchronousd Renal Mildly increased Prednisone, dapsone, Surgery Remissione Alive, Uvular swelling believed abdominal pain, carcinoma RF level (negative fluocinolone 0.05% 28 months to be secondary to HSP nausea, diarrhea CCP antibodies), cream, tacrolimus 0.1% per otolaryngologist microhematuria ointment evaluation malignancy andsolid-organ HSP 2 71/F Purpura, arthritis 3 months after Lung Increased ESR, Prednisone Surgery, Remissione Deceased, None carcinoma microhematuria, chemotherapy, 14 months proteinuria irradiation 3 68/M Purpura, bilateral Synchronousd Prostate Increased ESR Prednisone, HCQ, None Partial Deceased, Bilateral pulmonary pulmonary carcinoma and CRP levels, triamcinolone 0.1% remissionf 10 months infiltrates believed to be infiltrates, arthritis decreased C3 level, cream secondary to HSP per microhematuria pulmonologist evaluation aSkin biopsy findings showed leukocytoclastic vasculitis in all cases. Acta Derm Venereol 92 Acta DermVenereol bFrom diagnosis of HSP. cBriefly reported in Podjasek et al. (1). dOccurred within 1 month of each other. eAfter combination of cancer treatment and immunosuppressive therapy. fAfter treatment of vasculitis with glucocorticoids or other immunosuppressive agent. CCP: cyclic citrullinated peptide; CRP: C-reactive protein; DIF: direct immunofluorescence; ESR: erythrocyte sedimentation rate; HCQ: hydroxychloroquine; RF: rheumatoid factor. 389 390 J. O. Podjasek et al. and direct immunofluorescence demonstrated IgA and C3 HSP is 87.1% sensitive and 87.7% specific when at deposition within papillary dermal blood vessels. Moreover, least 2 of the following features are present: palpable on renal biopsy to evaluate the hematuria and proteinuria, im- munofluorescent histological analysis showed segmental and purpura, bowel angina, age 20 years or younger at diffuse granular mesangial staining for IgA and C3, consistent onset, and histological changes of leukocytoclastic
Recommended publications
  • Necrotizing Leukocytoclastic Vasculitis Mimicking Necrotizing Fasciitis: a Case Report
    International Journal of Research in Orthopaedics Soylemez MS et al. Int J Res Orthop. 2016 Sep;2(3):194-198 http://www.ijoro.org DOI: http://dx.doi.org/10.18203/issn.2455-4510.IntJResOrthop20163130 Case Report Necrotizing leukocytoclastic vasculitis mimicking necrotizing fasciitis: a case report Mehmet Salih Soylemez1*, Korhan Ozkan2, Bulent Kılıc3, Samet Erinc2, Irfan Esenkaya2, Bahar Ceyran4 1 Department of Orthopaedics and Traumatology, Bingol State Hospital, Bingol, Turkey 2Department of Orthopaedics and Traumatology, 4Department of Pathology, Istanbul Medeniyet University, Goztepe Training and Research Hospital 3Department of Health Sciences, Istanbul Gelisim University, Istanbul, Turkey Received: 19 July 2016 Accepted: 11 August 2016 *Correspondence: Dr. Mehmet Salih Soylemez, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT There are several subtypes of necrotizing leukocytoclastic vasculitis, which are classified according to their morphological features in biopsy specimens using immunofluorescence microscopy. Necrotizing leukocytoclastic vasculitis is limited to the skin, predominantly that of the lower extremities, and usually spares the palms and soles. The most common skin manifestation is palpable purpura. Other skin manifestations include maculopapular rash, bullae, papules, nodules, ulcers and livedo reticularis. There is no specific laboratory test to determine the diagnosis. There are various diseases presenting with these nonspecific symptoms, and a rapid differential diagnosis must be conducted, because the appropriate differentiation and diagnosis markedly influence the treatment strategy and survival of patients.
    [Show full text]
  • Visual Recognition of Autoimmune Connective Tissue Diseases
    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
    [Show full text]
  • Review Cutaneous Patterns Are Often the Only Clue to a a R T I C L E Complex Underlying Vascular Pathology
    pp11 - 46 ABstract Review Cutaneous patterns are often the only clue to a A R T I C L E complex underlying vascular pathology. Reticulate pattern is probably one of the most important DERMATOLOGICAL dermatological signs of venous or arterial pathology involving the cutaneous microvasculature and its MANIFESTATIONS OF VENOUS presence may be the only sign of an important underlying pathology. Vascular malformations such DISEASE. PART II: Reticulate as cutis marmorata congenita telangiectasia, benign forms of livedo reticularis, and sinister conditions eruptions such as Sneddon’s syndrome can all present with a reticulate eruption. The literature dealing with this KUROSH PARSI MBBS, MSc (Med), FACP, FACD subject is confusing and full of inaccuracies. Terms Departments of Dermatology, St. Vincent’s Hospital & such as livedo reticularis, livedo racemosa, cutis Sydney Children’s Hospital, Sydney, Australia marmorata and retiform purpura have all been used to describe the same or entirely different conditions. To our knowledge, there are no published systematic reviews of reticulate eruptions in the medical Introduction literature. he reticulate pattern is probably one of the most This article is the second in a series of papers important dermatological signs that signifies the describing the dermatological manifestations of involvement of the underlying vascular networks venous disease. Given the wide scope of phlebology T and its overlap with many other specialties, this review and the cutaneous vasculature. It is seen in benign forms was divided into multiple instalments. We dedicated of livedo reticularis and in more sinister conditions such this instalment to demystifying the reticulate as Sneddon’s syndrome. There is considerable confusion pattern.
    [Show full text]
  • Update on Vasculitis: Overview and Relevant
    An Bras Dermatol. 2020;95(4):493---507 Anais Brasileiros de Dermatologia www.anaisdedermatologia.org.br REVIEW Update on vasculitis: overview and relevant dermatological aspects for the clinical and ଝ,ଝଝ histopathological diagnosis --- Part II a,∗ b Thâmara Cristiane Alves Batista Morita , Paulo Ricardo Criado , b a a Roberta Fachini Jardim Criado , Gabriela Franco S. Trés , Mirian Nacagami Sotto a Department of Dermatology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil b Dermatology Discipline, Faculdade de Medicina do ABC, Santo André, SP, Brazil Received 8 December 2019; accepted 28 April 2020 Available online 24 May 2020 Abstract Vasculitis is a group of several clinical conditions in which the main histopathological KEYWORDS finding is fibrinoid necrosis in the walls of blood vessels. This article assesses the main derma- Anti-neutrophil tological aspects relevant to the clinical and laboratory diagnosis of small- and medium-vessel cytoplasmic cutaneous and systemic vasculitis syndromes. The most important aspects of treatment are also antibodies; discussed. Churg-Strauss © 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana,˜ S.L.U. This is an syndrome; open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Henoch-Schönlein purple; Leukocytoclastic cutaneous vasculitis; Systemic vasculitis; Vasculitis; Vasculitis associated with lupus of the central nervous system ଝ How to cite this article: Morita TCAB, Criado PR, Criado RFJ, Trés GFS, Sotto MN. Update on vasculitis: overview and relevant dermato- logical aspects for the clinical and histopathological diagnosis --- Part II. An Bras Dermatol. 2020;95:493---507. ଝଝ Study conducted at the Department of Dermatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
    [Show full text]
  • Disseminated Intravascular Coagulation and Coagulation Disorders Carl-Erik Dempfle
    Disseminated intravascular coagulation and coagulation disorders Carl-Erik Dempfle Purpose of review Abbreviations An update on recent developments in diagnosis and treatment aPTT activated partial thromboplastin time of disseminated intravascular coagulation. DAA drotrecogin a (activated) DIC disseminated intravascular coagulation Recent findings FRM fibrin-related marker Disseminated intravascular coagulation is defined as a typical ISTH International Society for Thrombosis and Hemostasis disease condition with laboratory findings indicating massive # coagulation activation and reduction in procoagulant capacity. 2004 Lippincott Williams & Wilkins 0952-7907 Clinical syndromes associated with the condition are consumption coagulopathy, sepsis-induced purpura fulminans, and viral hemorrhagic fevers. Consumption coagulopathy is Introduction observed in patients with sepsis, aortic aneurysms, acute The diagnosis of disseminated intravascular coagulation promyelocytic leukemia, and other disseminated malignancies. (DIC) is based on the combination of a disease condition Sepsis-induced purpura fulminans is characterized by with laboratory findings indicating massive coagulation microvascular occlusion causing hemorrhagic necrosis of the activation and reduction in procoagulant capacity (Table skin and organ failure. Viral hemorrhagic fevers result in 1). Current scoring systems include elevated fibrin- massively increased tissue factor production in monocytes and related markers (FRMs), prolonged prothrombin time, macrophages, inducing microvascular
    [Show full text]
  • Update on Vasculitis: Overview and Relevant
    An Bras Dermatol. 2020;95(4):493---507 Anais Brasileiros de Dermatologia www.anaisdedermatologia.org.br REVIEW Update on vasculitis: overview and relevant dermatological aspects for the clinical and ଝ,ଝଝ histopathological diagnosis --- Part II a,∗ b Thâmara Cristiane Alves Batista Morita , Paulo Ricardo Criado , b a a Roberta Fachini Jardim Criado , Gabriela Franco S. Trés , Mirian Nacagami Sotto a Department of Dermatology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil b Dermatology Discipline, Faculdade de Medicina do ABC, Santo André, SP, Brazil Received 8 December 2019; accepted 28 April 2020 Available online 24 May 2020 Abstract Vasculitis is a group of several clinical conditions in which the main histopathological KEYWORDS finding is fibrinoid necrosis in the walls of blood vessels. This article assesses the main derma- Anti-neutrophil tological aspects relevant to the clinical and laboratory diagnosis of small- and medium-vessel cytoplasmic cutaneous and systemic vasculitis syndromes. The most important aspects of treatment are also antibodies; discussed. Churg-Strauss © 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana,˜ S.L.U. This is an syndrome; open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Henoch-Schönlein purple; Leukocytoclastic cutaneous vasculitis; Systemic vasculitis; Vasculitis; Vasculitis associated with lupus of the central nervous system ଝ How to cite this article: Morita TCAB, Criado PR, Criado RFJ, Trés GFS, Sotto MN. Update on vasculitis: overview and relevant dermato- logical aspects for the clinical and histopathological diagnosis --- Part II. An Bras Dermatol. 2020;95:493---507. ଝଝ Study conducted at the Department of Dermatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
    [Show full text]
  • Dermatological Indications of Disease - Part II This Patient on Dialysis Is Showing: A
    “Cutaneous Manifestations of Disease” ACOI - Las Vegas FR Darrow, DO, MACOI Burrell College of Osteopathic Medicine This 56 year old man has a history of headaches, jaw claudication and recent onset of blindness in his left eye. Sed rate is 110. He has: A. Ergot poisoning. B. Cholesterol emboli. C. Temporal arteritis. D. Scleroderma. E. Mucormycosis. Varicella associated. GCA complex = Cranial arteritis; Aortic arch syndrome; Fever/wasting syndrome (FUO); Polymyalgia rheumatica. This patient missed his vaccine due at age: A. 45 B. 50 C. 55 D. 60 E. 65 He must see a (an): A. neurologist. B. opthalmologist. C. cardiologist. D. gastroenterologist. E. surgeon. Medscape This 60 y/o male patient would most likely have which of the following as a pathogen? A. Pseudomonas B. Group B streptococcus* C. Listeria D. Pneumococcus E. Staphylococcus epidermidis This skin condition, erysipelas, may rarely lead to septicemia, thrombophlebitis, septic arthritis, osteomyelitis, and endocarditis. Involves the lymphatics with scarring and chronic lymphedema. *more likely pyogenes/beta hemolytic Streptococcus This patient is susceptible to: A. psoriasis. B. rheumatic fever. C. vasculitis. D. Celiac disease E. membranoproliferative glomerulonephritis. Also susceptible to PSGN and scarlet fever and reactive arthritis. Culture if MRSA suspected. This patient has antithyroid antibodies. This is: • A. alopecia areata. • B. psoriasis. • C. tinea. • D. lichen planus. • E. syphilis. Search for Hashimoto’s or Addison’s or other B8, Q2, Q3, DRB1, DR3, DR4, DR8 diseases. This patient who works in the electronics industry presents with paresthesias, abdominal pain, fingernail changes, and the below findings. He may well have poisoning from : A. lead. B.
    [Show full text]
  • Conflict of Interest Cutaneous Vasculitis
    Cutaneous Vasculitis: Texas Dermatologic Society 2018 Joseph L. Jorizzo, MD Professor, Former and Founding Chair Department of Dermatology Wake Forest School of Medicine Winston-Salem, NC – USA Professor of Clinical Dermatology Department of Dermatology Weill Cornell Medical College New York, NY - USA Conflict of Interest Amgen – Advisory Board – Honoraria Cutaneous Vasculitis Key Features Cutaneous signs of vasculitis are a reflection of the size of the vessels involved Vasculitis can be limited to the small vessels of the skin or it can be a sign of life-threatening internal organ invovlement The clinical diagnosis of cutaneous vasculitis requires histopathologic confirmation and multiple biopsies may be required 1 Vasculitis: 2018 Classification Problems: The example of the ACR Criteria Age at disease onset > 16 years Medication at disease onset Palpable purpura Biopsy including arteriole and venule with histologic change showing granulocytes in perivascular or extravascular location Three criteria are required ARTHRITIS & RHEUMATISM Vol. 65, No.1, Jan 2013, pp1-11 DOI 10.1002/art37715 2013, American College of Rheumatology Arthritis & Rheumatism An Official Journal of the American College of Rheumatology www.arthritisheum.org and wileyonlinelibrary.com SPECIAL ARTICLE 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides J.C. Jennette, 1 R.J. Falk, 1, P.A. Bacon,2 N. Basu,3 M.C. Cid,4 F. Ferrario, 5 L.F. Flores-Suarez,6 W.L. Gross,7 L. Guillevin,8 E.C. Hagen,9 G.S. Hoffman,10 D.R. Jayne,11 C.G.M. Kallenberg,12 P. Lamprecht,13 C.A. Langford,10 R. A. Luqmani,14 A. D. Mahr, 15 E.L.
    [Show full text]
  • ESVM Guidelines – the Diagnosis and Management of Raynaud's Phenomenon
    413 Review ESVM guidelines – the diagnosis and management of Raynaud’s phenomenon Writing group Jill Belch1, Anita Carlizza2, Patrick H. Carpentier3, Joel Constans4, Faisel Khan1, and Jean-Claude Wautrecht5 1 University of Dundee School of Medicine, Dundee, United Kingdom 2 Azienda Ospedaliera S.Giovanni-Addolorata, Rome, Italy 3 Grenoble University Hospital, Grenoble, France 4 Hopital St Andre, Bordeaux, France 5 Cliniques universitaires de Bruxelles, Brussels, Belgium ESVM board authors Adriana Visona6, Christian Heiss7, Marianne Brodeman8, Zsolt Pécsvárady9, Karel Roztocil10, Mary-Paula Colgan11, Dragan Vasic12, Anders Gottsäter13, Beatrice Amann-Vesti14, Ali Chraim15, Pavel Poredoš16, Dan-Mircea Olinic17, Juraj Madaric18, and Sigrid Nikol19 6 Angiology Unit, Azienda ULSS 2, Marca Trevigiana, Treviso, Italy 7 Department of Cardiology, Pulmonology and Vascular Medicine, Düsseldorf, Germany 8 Division of Angiology, Medical University, Graz, Austria 9 Head of 2nd Dept. of Internal Medicine, Vascular Center, Flor Ferenc Teaching Hospital, Kistarcsa, Hungary 10 Institute of Clinical and Experimental Medicine, Prague, Czech Republic 11 St. James’s Hospital and Trinity College, Dublin, Ireland 12 Clinical Centre of Serbia, Belgrade, Serbia 13 Department of Vascular Diseases, Skåne University Hospital, Sweden 14 Clinic for Angiology, University Hospital Zurich, Switzerland 15 Department of Vascular Surgery, Cedrus Vein and Vascular Clinic, Lviv Hospital, Lviv, Ukraine 16 University Medical Centre Ljubljana, Slovenia 17 Medical Clinic no. 1,
    [Show full text]
  • Cutaneous Manifestations of SLE and Other Connective Tissue Diseases
    Cutaneous manifestations of SLE and other connective tissue diseases Objectives : ● Not given عبدهللا الناصر، عبدالرحمن المالكي، عبدالكريم المهيدلي، محمد خوجه :Done by مؤيد اليوسف :Revised by Before you start.. CHECK THE EDITING FILE Sources: notes + FITZPATRICK color atlas +435 team [ Color index: Important|435 notes |doctor notes|Extra] (Connective Tissue Diseases) • Lupus Erythematosus - Acute Cutaneous Lupus Erythematosus (ACLE) - Subacute Cutaneous Lupus Erythematosus (SCLE) - Discoid Lupus Erythematosus (DLE) - Lupus Erythematosus Tumidus - Lupus Panniculitis - Neonatal Lupus Erythematosus • Dermatomyositis • Scleroderma(systemic sclerosis) • Morphea & Lichen Sclerosus • Other Rheumatologic Disease - Still’s disease - Relapsing Polychondritis - Sjogren’s syndrome - Mixed connective tissue disease We’ll only mention the first 4. This is just to show you connective tissue diseases in dermatology. 1- Lupus Erythematosus (LE): ● A multisystem disorder that predominantly affects the skin.If we have a patient with a non specific skin lesions we have to put lupus in the DDx. ● Its course and organs involvement are unpredictable (Great mimicker). ● It ranges from life threatening manifestations of SLE to the limited and exclusive skin involvement in chronic cutaneous lupus. ● A common classification of cutaneous LE: Specific vs non-specific. - Specific: Acute (ACLE), subacute (SCLE), chronic (DLE, tumid lupus, lupus panniculitis). The three major specific types are not mutually exclusive. In a given patient, more than one type may occur. - Non-specific: Raynaud’s, Livedo Reticularis, Palmar Erythema, Periungual Telangiectasias, vasculitis, diffuse non scarring alopecia, ulcers. Risk for systemic disease: ● Acute cutaneous LE (ACLE) 100% ● Subacute cutaneous LE (SCLE) 50% ● Chronic cutaneous LE (CCLE) (DLE) 10% - Epidemiology: (females more affected) ● Incidence of CLE in Sweden and USA is 4/100,000.
    [Show full text]
  • NPIAP 1 Skin Manifestations with COVID-19
    Skin Manifestations with COVID-19: The Purple Skin and Toes that you are seeing may not be Deep Tissue Pressure Injury. An NPIAP White Paper Many reports are occurring concerning areas of purpuric/purple skin and purple toe lesions in patients diagnosed with COVID-19 (SARS-CoV-2) (Figure 1). Wound care providers are being asked if these skin lesions are forms of Deep Tissue Pressure Injury and/or “skin failure”. Early reports of COVID-19 related skin changes included rashes, acral areas of erythema with vesicles or pustules (pseudo-chilblain), other vesicular eruptions, urticarial lesions, maculopapular eruptions, and livedo or necrosis.1-4 The pattern and presentation of skin manifestations with COVID-19 is more than rashes. The purpose of this paper is to guide the wound care clinician in determining if the “purple skin” being seen is a deep tissue pressure injury or a cutaneous manifestation of COVID-19. Figure 1. Right Buttock on Day 1 Right Buttock, sacrum and coccyx on Day 3 Photos used with permission of Beaumont Health, Royal Oak MI Background. The true incidence of COVID-19 related skin injury is unknown at this time; however, NPIAP board members practicing in COVID-19 hotspots and others who are submitting inquiries to the NPIAP Website are reporting purple discoloration of the skin and soft tissue not exposed to pressure. One form is being referred to as a novel phenomenon called "COVID toes" (i.e. deep red or purple appearance of the toes). Clinicians are requesting guidance from NPIAP regarding the differential diagnosis of these injuries from pressure injuries.
    [Show full text]
  • Diagnosis and Management of Obscure Gastrointestinal Bleeding
    BRITISH MEDICAL JOURNAL 9 SEPTEMBER 1978 751 Br Med J: first published as 10.1136/bmj.2.6139.751 on 9 September 1978. Downloaded from Clinical Topics Diagnosis and management of obscure gastrointestinal bleeding D TARIN, D J ALLISON, I M MODLIN, G NEALE British MedicalJournal, 1978, 2, 751-754 the bowel, the use of radiochromium-labelled red cells, and string tests are cumbersome and inefficient, and inspecting the bowel at laparotomy is usually unrewarding. New endoscopic Summary and conclusions techniques may occasionally show a vascular malformation, but in studying 12 patients over the past two years we have found Twelve consecutive patients presenting with unexplained angiography as introduced by Baum et al7 to be the most recurrent gastrointestinal bleeding were investigated by effective diagnostic method.8 Furthermore, using the specialised selective visceral angiography. A cause for the bleeding techniques described below we have studied the histology of was shown in all 12 cases, and in eight the lesion respon- vascular lesions of the intestine in detail. sible was diagnosed radiologically as an area of angio- dysplasia. Abnormal areas were pinpointed by fluoro- scopy and examination of the resected bowel with a dissecting microscope after injecting the vessels with Patients and methods barium. Histologically these areas had various micro- We studied 12 consecutive patients (five men, seven women) vascular abnormalities. referred to the gastrointestinal unit, Hammersmith Hospital, for Angiodysplasia is a useful descriptive radiological investigation of gastrointestinal bleeding from an unknown site term, but does not seem to represent a single pathological (table). Eight had undergone repeated investigations over periods entity.
    [Show full text]